www.vielabio.com

Contact Information:

Annie Olson
Cell:  651-246-8180
OlsonA@vielabio.com

Cheryl Kennedy
Cell: 407-202-9433
KennedyC@vielabio.com

 

Virtual Exhibit Hall Home

Viela is dedicated to the development and commercialization of novel, life-changing medicines for patients with a wide range of autoimmune and severe inflammatory diseases. Our team is comprised of passionate, talented, world-class leaders with diverse experience in the autoimmune disease space and our research focuses on well-established critical biological pathways shared across multiple indications. We believe that our approach – which targets the underlying molecular pathogenesis of the disease – enables us to develop more precise therapies, identify patients more likely to respond to treatment and pursue multiple indications for each of our product candidates.
In June 2020, we announced the FDA approval of a treatment for neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquarporin-4 (AQP4) antibody positive. We continue to advance clinical trials in various indications including myasthenia gravis, IgG4-related disease, and kidney transplant rejection. Our pipeline also includes novel candidates which we are pursuing for the treatment of a variety of serious and debilitating autoimmune diseases.

Uplizna Package Insert

Uplizna PI Based Brochure

Uplizna Patient Start Form Digital